Q-omics provides the consensus-scored NICN2P profile across patient tissues and cancer cell-line models. NICN2P expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, NICN2P is differentially expressed in 5, with the highest sampling consensus in BRCA. Additionally, NICN2P RNA expression shows 6,432 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight LIHC, BRCA, and STAD as cancer lineages where NICN2P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NICN2P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NICN2P survival associations across molecular data types. NICN2P RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NICN2P RNA expression–survival associations across cancer types. High NICN2P expression shows unfavorable associations in LIHC, LUSC, SKCM and DLBC, but favorable associations in THCA and READ. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for NICN2P RNA expression.
This table summarizes NICN2P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for NICN2P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NICN2P shows lower tumor expression in BRCA, THCA, KIRC and LUAD and higher tumor expression in COAD. The BRCA box plot shows higher NICN2P RNA expression in normal versus tumor tissue (log2 FC = −0.025, t-test p = .022).
This table shows molecular features associated with NICN2P in patient tissues and cancer cell lines. In patient samples, NICN2P shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
